Good to hear RGS is progressing its immuno-oncolcogy area. The phase 1 ACTIVATE trial has been a challenging recruit and it will be interesting to see the reporting this HY. I addition I have read that RGS is doing pre-clinical work with RGSH4K in combination with an ant PD1 immune checkpoint inhibitor (ICI).
This in combination with its stem cells and secretions areas should be a good news flow coming up.
RGS Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
